Basic Research
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 7, 2006; 12(13): 2047-2052
Published online Apr 7, 2006. doi: 10.3748/wjg.v12.i13.2047
Table 1 Impact of QGHXF on ALT, AST, ALP, and -GT in AF rats (mean±SD)
GroupnALT(nkat/L)AST(nkat/L)ALP(nkat/L)GGT(nkat/L)
Norma12464  ±  90 b1156  ± 2 50b1065  ±  315b360  ±  98b
CCl412674  ±  1721678  ±  293a1695  ±  406a748  ±  242a
Model10926  ±  1543344  ±  3302806  ±  6391376  ±  215
Low dose11747  ±  1132552  ±  388b1748  ±  462a982  ±  236a
Moderate dose10718  ±  1562215  ±  650b1632  ±  502a869  ±  303a
High dose10615  ±  190bc1972  ±  366bc1570 ±  497a770  ±  240b
XCH108672777 ± 608a2413  ±  609a768  ±  292b
Table 2 Effect of QGHXF on proliferation and cell cycle of HSC (n=6; mean±SD)
GroupApoptotic rate (%)Cell cycle
G0/G1SG2/MPI value (%)
Normal4.47  ±  0.879.30  ±  1.031.69  ±  0.7319.02  ±  1.6720.71  ±  1.03
Low dose10.07  ±  1.14a37.47 ±  0.68b1.46  ±  0.46a61.07  ±  0.33b62.53  ±  0.68b
Moderate dose13.79  ± 2.26a68.31  ±  0.92a2.11  ±  0.46a29.58  ± 1.3831.69  ±  0.92a
High dose22.4  ±  3.13b71.25  ±  1.05b2.70  ±  0.4626.06  ±  1.47b28.75  ±  1.05b
Model6.58  ±  1.0464.55  ±  1.533.69  ±  0.6631.76  ±  0.8735.45  ±  1.53